Versant Venture Management LLC's Q3 2023 13F: 1 new position, 1 exit
Form 13F-HR for the quarter ended Sep 30, 2023 · filed Nov 3, 2023 · 8 reported positions · accession 0000950123-23-009395
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| New | RayzeBio, Inc. (RYZB) | — | 60.9% | +60.9 pts | +5.16M sh | new |
| Exited | CymaBay Therapeutics, Inc. (CBAY) | 7.1% | — | −7.1 pts | −544K sh | −100% |
| Reduced | Minerva Surgical Inc. (UTRS) | 0.5% | 0.1% | −0.4 pts | −1.59M sh | −95% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
Changes in the top 10 this quarter: RYZB entered · CBAY left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | RayzeBio, Inc. (RYZB) | 0.0% | 60.9% | Entered the top 10 |
| 2 | Repare Therapeutics, Inc. (RPTX) | 33.2% | 17.0% | |
| 3 | CRISPR Therapeutics AG (CRSP) | 33.2% | 12.0% | |
| 4 | Adverum Biotechnologies, Inc. (ADVM) | 9.6% | 4.0% | |
| 5 | Gritstone Oncology, Inc. (GRTS) | 8.2% | 3.3% | |
| 6 | Passage Bio, Inc. (PASG) | 5.5% | 1.7% | |
| 7 | Aligos Therapeutics, Inc. (ALGS) | 2.7% | 0.9% | |
| 8 | Minerva Surgical Inc. (UTRS) | 0.5% | 0.1% | |
| — | CymaBay Therapeutics, Inc. (CBAY) | 7.1% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).